Cardlytics, Inc.'s (NASDAQ:CDLX) Chief Legal & Privacy Officer, Nicholas Hollmeyer, has recently sold shares in the company. According to a new SEC filing, Hollmeyer sold 276 shares of Cardlytics' common stock on April 23, 2024, for a total value exceeding $3,500. The shares were sold at prices ranging from $12.38 to $12.925, with a weighted average sales price of $12.758.
The transactions have slightly altered Hollmeyer's holdings in the company, with his ownership standing at 71,761 shares following the sale. The sale was reportedly made to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) on April 20, 2024. It's noted in the filing that these shares were not sold for any purpose other than to meet the tax requirements.
In a related transaction, Hollmeyer also acquired 682 shares through the vesting of RSUs on April 22, 2024. Each RSU represents a contingent right to receive one share of Cardlytics' common stock. This award was part of an RSU grant that originally totaled 2,727 shares, with a vesting schedule spread over four years. The most recent vesting event did not involve any cash transaction, as it pertained to the conversion of RSUs to common stock.
Investors and followers of Cardlytics, Inc. may find these transactions of interest as they reflect the activities of the company's insiders. For more detailed information, the SEC filing can be consulted, and the company can provide full details regarding the number of shares sold at each price upon request.
InvestingPro Insights
Amidst the recent insider transactions by Cardlytics, Inc.'s (NASDAQ:CDLX) Chief Legal & Privacy Officer, Nicholas Hollmeyer, the company's stock performance and financial health remain areas of interest for investors. Cardlytics has been experiencing notable shifts in its stock valuation and financial metrics, as reflected in real-time data from InvestingPro.
Cardlytics' market capitalization stands at $594.95 million, indicating the size of the company in the competitive market landscape. Despite the challenges, Cardlytics has shown a strong return over the last three months, with a 99.68% price total return, which could signal a positive trend for the company's future performance. Additionally, analysts have revised their earnings upwards for the upcoming period, suggesting a potential improvement in the company's profitability. This aligns with the prediction that Cardlytics will be profitable this year, an important turnaround considering the company has not been profitable over the last twelve months.
InvestingPro Tips also highlight that Cardlytics operates with a moderate level of debt and that its liquid assets exceed short-term obligations, which could provide some financial stability. However, the stock has been marked by high price volatility, and it has fared poorly over the last month with a -20.88% price total return. This could be a factor for investors to consider when assessing the risk associated with Cardlytics' shares.
For investors seeking a more comprehensive analysis, there are additional InvestingPro Tips available that delve deeper into the company's financial health and stock performance. To access these insights and make informed investment decisions, investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.